Clinical trial failure or delay
The company’s value depends on Antineoplastons progressing through clinical development and ultimately gaining approval.
- Scope
- Antineoplaston development program
- Materiality
- high
Burzynski Research Institute Inc
Burzynski Research Institute, Inc. is a Delaware-incorporated research company focused on developing and studying Antineoplastons, a group of growth-inhibiting peptides, amino acid derivatives, and organic acids that the company believes may be useful in cancer treatment. Its activities are centered on clinical research rather than commercial sales, and the company states that Antineoplastons are currently provided solely for use by Stanislaw R. Burzynski, M.D., Ph.D. in clinical research. The company has not generated significant operating revenue since inception and does not expect meaningful revenue until, if ever, the products receive regulatory approval. In practice, the business is a highly specialized, founder-linked research operation funded primarily through arrangements with Dr. Burzynski and his medical practice.
| % | |
|---|---|
| Antineoplaston formulations | 0% Natural and synthetic compounds developed for cancer research and clinical testing. |
| Clinical research services | 70% Research activities, trial operations, and related scientific support for Antineoplaston studies. |
| Consulting services | 30% Limited consulting work tied to drug research and development activities. |
The company’s primary end user is its own clinical research program, since Antineoplastons are currently used only in...
- Internal clinical research useprimary
The company currently supplies Antineoplastons solely for use in Dr. Burzynski's clinical research program.
- Future oncology treatment marketemerging
If approved, the products would be sold to cancer patients through physicians or treatment centers.
- External R&D services clientssecondary
Other companies may pay for research and development services, though this appears limited and non-core.
The company is incorporated in Delaware and operates in the United States, where its research, funding arrangements,...
- •Incorporated in Delaware and based in the United States
- •Research and clinical activity are U.S.-centered
- •No disclosed international commercial sales footprint
- •Future commercialization would begin in the U.S. or Canada if approved
- •Operations are heavily shaped by FDA regulatory requirements
The company’s strategy is to continue developing Antineoplastons through clinical research and to preserve the option...
01
Continue clinical development of Antineoplastonsshort-term
Regulatory approval is the only path to meaningful commercial revenue.
02
Maintain regulatory and orphan-drug positioningmedium-term
Orphan designation and FDA engagement support the long-term approval pathway.
03
Preserve funding continuityshort-term
The company cannot sustain research without external support from Dr. Burzynski or new financing.
The company faces very high development risk because its product candidates have not been approved and may never reach...
Funding concentration
Operations are funded entirely by Dr. Burzynski and his medical practice, creating a single-point failure.
- Scope
- All research and operating activities
- Materiality
- high
FDA clinical hold
A hold prevents or limits enrollment and slows the path to data generation and approval.
- Scope
- BT-55 and other active studies
- Materiality
- high
Key-person dependence
The company relies on a very small number of scientific and executive personnel for strategy and operations.
- Scope
- Management and scientific leadership
- Materiality
- high
Intellectual property disputes
Biotech patent and ownership challenges could force licensing, royalties, or loss of rights.
- Scope
- Future patents and proprietary know-how
- Materiality
- medium
Related-party contributions
Can materially change the presentation of operating performance and capital structure
Going-concern and liquidity assessment
Critical for evaluating solvency and continuity of research operations
Internal controls
Could affect the accuracy and timeliness of financial reporting
Inhibitor Therapeutics, Inc.
INTI · Pharmaceutical Preparations
BriaCell Therapeutics Corp.
BCTX · Pharmaceutical Preparations
Foghorn Therapeutics Inc.
FHTX · Pharmaceutical Preparations
Zymeworks Inc.
ZYME · Pharmaceutical Preparations
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Annexon, Inc.
ANNX · Pharmaceutical Preparations
: 11/08/2026